PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.36%
Positive revenue growth while AVGO is negative. John Neff might see a notable competitive edge here.
5.20%
Gross profit growth similar to AVGO's 5.31%. Walter Schloss would assume both firms track common industry trends.
27.49%
EBIT growth above 1.5x AVGO's 15.11%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
27.49%
Operating income growth above 1.5x AVGO's 15.11%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
23.82%
Net income growth 1.25-1.5x AVGO's 17.91%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
21.21%
EPS growth 1.25-1.5x AVGO's 16.67%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
21.21%
Diluted EPS growth 1.25-1.5x AVGO's 15.09%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
-5.11%
Share reduction while AVGO is at 0.80%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-4.41%
Reduced diluted shares while AVGO is at 1.18%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-1.27%
Dividend reduction while AVGO stands at 8.80%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-45.08%
Negative OCF growth while AVGO is at 9.61%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-89.56%
Negative FCF growth while AVGO is at 0.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
74.38%
10Y revenue/share CAGR at 75-90% of AVGO's 83.90%. Bill Ackman would press for new markets or product lines to narrow the gap.
3.88%
5Y revenue/share CAGR under 50% of AVGO's 83.90%. Michael Burry would suspect a significant competitive gap or product weakness.
17.88%
3Y revenue/share CAGR at 75-90% of AVGO's 22.19%. Bill Ackman would expect new product strategies to close the gap.
320.67%
10Y OCF/share CAGR 1.25-1.5x AVGO's 224.24%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
13.07%
Below 50% of AVGO's 224.24%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
174.85%
Positive 3Y OCF/share CAGR while AVGO is negative. John Neff might see a big short-term edge in operational efficiency.
227.65%
Below 50% of AVGO's 534.55%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
175.68%
Below 50% of AVGO's 534.55%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
166.95%
3Y net income/share CAGR above 1.5x AVGO's 14.24%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
243.72%
10Y equity/share CAGR in line with AVGO's 254.76%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
48.67%
Below 50% of AVGO's 254.76%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
47.89%
3Y equity/share CAGR at 50-75% of AVGO's 71.89%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.50%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
0.18%
Inventory shrinking or stable vs. AVGO's 5.24%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
-11.31%
Negative asset growth while AVGO invests at 5.73%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.86%
We have a declining book value while AVGO shows 4.57%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-3.53%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
1.40%
R&D dropping or stable vs. AVGO's 6.54%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-0.33%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.